401 related articles for article (PubMed ID: 25169932)
21. Stathmin and microtubules regulate mitotic entry in HeLa cells by controlling activation of both Aurora kinase A and Plk1.
Silva VC; Cassimeris L
Mol Biol Cell; 2013 Dec; 24(24):3819-31. PubMed ID: 24152729
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer.
Yao D; Gu P; Wang Y; Luo W; Chi H; Ge J; Qian Y
Biochem Cell Biol; 2018 Jun; 96(3):317-325. PubMed ID: 29040814
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
24. Imbalance of the spindle-assembly checkpoint promotes spindle poison-mediated cytotoxicity with distinct kinetics.
Zeng X; Xu WK; Lok TM; Ma HT; Poon RYC
Cell Death Dis; 2019 Apr; 10(4):314. PubMed ID: 30952840
[TBL] [Abstract][Full Text] [Related]
25. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
[TBL] [Abstract][Full Text] [Related]
26. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
27. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
Wäsch R; Hasskarl J; Schnerch D; Lübbert M
Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841
[TBL] [Abstract][Full Text] [Related]
28. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
29. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Menendez JA
Cell Cycle; 2011 Apr; 10(8):1295-302. PubMed ID: 21474997
[TBL] [Abstract][Full Text] [Related]
30. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
31. Polo-like kinase-1 regulates kinetochore-microtubule dynamics and spindle checkpoint silencing.
Liu D; Davydenko O; Lampson MA
J Cell Biol; 2012 Aug; 198(4):491-9. PubMed ID: 22908307
[TBL] [Abstract][Full Text] [Related]
32. PLK1 inhibitors: setting the mitotic death trap.
Plyte S; Musacchio A
Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
[TBL] [Abstract][Full Text] [Related]
33. Aurora B kinase activation requires survivin priming phosphorylation by PLK1.
Chu Y; Yao PY; Wang W; Wang D; Wang Z; Zhang L; Huang Y; Ke Y; Ding X; Yao X
J Mol Cell Biol; 2011 Aug; 3(4):260-7. PubMed ID: 21148584
[TBL] [Abstract][Full Text] [Related]
34. Selectivity-determining residues in Plk1.
Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
[TBL] [Abstract][Full Text] [Related]
35. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
[TBL] [Abstract][Full Text] [Related]
36. Plk1 and Mps1 Cooperatively Regulate the Spindle Assembly Checkpoint in Human Cells.
von Schubert C; Cubizolles F; Bracher JM; Sliedrecht T; Kops GJPL; Nigg EA
Cell Rep; 2015 Jul; 12(1):66-78. PubMed ID: 26119734
[TBL] [Abstract][Full Text] [Related]
37. Polo and Aurora kinases: lessons derived from chemical biology.
Taylor S; Peters JM
Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
[TBL] [Abstract][Full Text] [Related]
38. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
Ritter A; Friemel A; Kreis NN; Louwen F; Yuan J
Oncotarget; 2016 Dec; 7(51):84271-84285. PubMed ID: 27713178
[TBL] [Abstract][Full Text] [Related]
39. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
[TBL] [Abstract][Full Text] [Related]
40. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
Wissing MD; Mendonca J; Kortenhorst MS; Kaelber NS; Gonzalez M; Kim E; Hammers H; van Diest PJ; Carducci MA; Kachhap SK
FASEB J; 2013 Oct; 27(10):4279-93. PubMed ID: 23884428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]